In the April 2018 issue of SLAS Discovery, a review article by Prof. Stefan Broer, Ph.D. of the Australian National University highlights opportunities and challenges in using amino acid transporters as drug targets. Amino Acid Transporters as Disease Modifiers and Drug Targets provides an overview of methods used to identify new inhibitors for amino acid transporters and outlines cell and organ function where these can be used to modulate, prevent or to treat diseases.
The review highlights the demand for better inhibitors of amino acid transport processes and outlines promising new strategies and targets to develop amino acid transporters as drug targets. Cancer cells, for instance, need essential amino acids to proliferate and metastasize. Amino acid transporters are essential for capturing of nutrients from blood vessels, which can be blocked by specific inhibitors.
This is an area of active research and a promising strategy to treat cancer. In the brain, amino acids serve as excitatory and inhibitory neurotransmitters, which are quickly removed to terminate nerve impulses. Amino acid transporters can be targeted to enhance inhibition or excitation, a strategy used to treat chronic pain and possibly schizophrenia and general brain damage.
Amino acids are generated from the breakdown of protein nutrition and are required as nutrients for cell growth, neurotransmission in the brain and cellular metabolism. Blocking some of these functions can treat diseases such as cancer, diabetes and chronic pain.
Amino Acid Transporters as Disease Modifiers and Drug Targets can be accessed for free (for a limited time) at http://journals.
A PDF of this article is available to credentialed media outlets upon request. Contact email@example.com.
About our Society and Journals
SLAS (Society for Laboratory Automation and Screening) is an international community of nearly 20,000 professionals and students dedicated to life sciences discovery and technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.
SLAS DISCOVERY: 2016 Impact Factor 2.444. Editor-in-Chief Robert M. Campbell, Ph.D., Eli Lilly and Company, Indianapolis, IN (USA). SLAS Discovery (Advancing Life Sciences R&D) was previously published (1996-2016) as the Journal of Biomolecular Screening (JBS).
SLAS TECHNOLOGY: 2016 Impact Factor 2.850. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore). SLAS Technology (Translating Life Sciences Innovation) was previously published (1996-2016) as the Journal of Laboratory Automation (JALA).
Follow SLAS on Twitter at @SLAS_Org.
Follow SLAS on Facebook at SocietyforLaboratoryAutomationandScreening.
Follow SLAS on YouTube at SLASvideo.
Follow SLAS Americas on LinkedIn at Society for Laboratory Automation and Screening (SLAS Americas).
Follow SLAS Europe on LinkedIn at Society for Laboratory Automation and Screening Europe (SLAS Europe).